These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31602975)

  • 1. Microfluidic Immunoassay System for Rapid Detection and Semi-Quantitative Determination of a Potential Serum Biomarker Mesothelin.
    Duan X; Zhao L; Dong H; Zhao W; Liu S; Sui G
    ACS Sens; 2019 Nov; 4(11):2952-2957. PubMed ID: 31602975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer.
    Kendrick ZW; Firpo MA; Repko RC; Scaife CL; Adler DG; Boucher KM; Mulvihill SJ
    HPB (Oxford); 2014 Jul; 16(7):670-6. PubMed ID: 24308545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases.
    Goricar K; Kovac V; Dodic-Fikfak M; Dolzan V; Franko A
    Radiol Oncol; 2020 Mar; 54(1):86-95. PubMed ID: 32187018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
    Iwahori K; Osaki T; Serada S; Fujimoto M; Suzuki H; Kishi Y; Yokoyama A; Hamada H; Fujii Y; Yamaguchi K; Hirashima T; Matsui K; Tachibana I; Nakamura Y; Kawase I; Naka T
    Lung Cancer; 2008 Oct; 62(1):45-54. PubMed ID: 18394747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment.
    Zhang X; Yu Y; Peer CJ; Landsman R; Skorupan N; Cao L; Alewine C
    Transl Oncol; 2022 Jul; 21():101440. PubMed ID: 35523008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness.
    Weidemann S; Perez D; Izbicki JR; Neipp M; Mofid H; Daniels T; Nahrstedt U; Jacobsen F; Bernreuther C; Simon R; Steurer S; Burandt E; Marx AH; Krech T; Clauditz TS; Jansen K
    Cancer Invest; 2021 Oct; 39(9):711-720. PubMed ID: 34143695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic bead droplet immunoassay of oligomer amyloid β for the diagnosis of Alzheimer's disease using micro-pillars to enhance the stability of the oil-water interface.
    Kim JA; Kim M; Kang SM; Lim KT; Kim TS; Kang JY
    Biosens Bioelectron; 2015 May; 67():724-32. PubMed ID: 25459055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia.
    Kaeding AJ; Barwe SP; Gopalakrishnapillai A; Ries RE; Alonzo TA; Gerbing RB; Correnti C; Loken MR; Broderson LE; Pardo L; Le QH; Tang T; Leonti AR; Smith JL; Chou CK; Xu M; Triche T; Kornblau SM; Kolb EA; Tarlock K; Meshinchi S
    Blood Adv; 2021 May; 5(9):2350-2361. PubMed ID: 33938941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of mesothelin expression in colorectal cancer disclosed by area-specific four-point tissue microarrays.
    Shiraishi T; Shinto E; Nearchou IP; Tsuda H; Kajiwara Y; Einama T; Caie PD; Kishi Y; Ueno H
    Virchows Arch; 2020 Sep; 477(3):409-420. PubMed ID: 32107600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elicit mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro.
    Miyazawa M; Iwahashi M; Ojima T; Katsuda M; Nakamura M; Nakamori M; Ueda K; Naka T; Hayata K; Iida T; Yamaue H
    Cancer Lett; 2011 Jun; 305(1):32-9. PubMed ID: 21397388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERC/mesothelin is expressed in human gastric cancer tissues and cell lines.
    Ito T; Kajino K; Abe M; Sato K; Maekawa H; Sakurada M; Orita H; Wada R; Kajiyama Y; Hino O
    Oncol Rep; 2014 Jan; 31(1):27-33. PubMed ID: 24146039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of a
    Hou X; Wang F; Meng X; Li D; Ding J; Chen Y; Wang Z; Zhu H; Yang Z
    Mol Pharm; 2022 Oct; 19(10):3623-3631. PubMed ID: 35904514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of protein immunoprecipitation-multiple reaction monitoring with ELISA for assay of biomarker candidates in plasma.
    Lin D; Alborn WE; Slebos RJ; Liebler DC
    J Proteome Res; 2013 Dec; 12(12):5996-6003. PubMed ID: 24224610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
    Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
    Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types.
    Lamberts LE; de Groot DJ; Bense RD; de Vries EG; Fehrmann RS
    Oncotarget; 2015 Sep; 6(29):28164-72. PubMed ID: 26172299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c
    Magalhaes I; Fernebro J; Abd Own S; Glaessgen D; Corvigno S; Remberger M; Mattsson J; Dahlstrand H
    Adv Ther; 2020 Dec; 37(12):5023-5031. PubMed ID: 33052561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The utility of a high-throughput scanning biosensor in the detection of the pancreatic cancer marker ULBP2.
    Chang YF; Yu JS; Chang YT; Su LC; Wu CC; Chang YS; Lai CS; Chou C
    Biosens Bioelectron; 2013 Mar; 41():232-7. PubMed ID: 22959016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma.
    Inami K; Kajino K; Abe M; Hagiwara Y; Maeda M; Suyama M; Watanabe S; Hino O
    Oncol Rep; 2008 Dec; 20(6):1375-80. PubMed ID: 19020717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Mesothelin Glycosylation in Pancreatic Cancer: Decreased Core Fucosylated Glycoforms in Pancreatic Cancer Patients' Sera.
    Duran A; Guerrero PE; Ortiz MR; Pérez Del Campo D; Castro E; Garcia-Velasco A; Fort E; de Llorens R; Saldova R; Llop E; Peracaula R
    Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous and highly sensitive detection of multiple breast cancer biomarkers in real samples using a SERS microfluidic chip.
    Zheng Z; Wu L; Li L; Zong S; Wang Z; Cui Y
    Talanta; 2018 Oct; 188():507-515. PubMed ID: 30029406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.